Karim Dabbagh

Karim Dabbagh is a distinguished leader in the pharmaceutical and biotech sectors, currently serving as a Member of the Board, President, and CEO of Silver Creek Pharmaceuticals since October 2024, and as Executive Chairman and Co-founder of Genevive since February 2023. With a wealth of experience, Karim held significant positions including Chairman of the Board of Directors at MaaT Pharma from June 2023 to June 2025, and President and CEO, as well as Chief Scientific Officer at Second Genome Inc. from August 2014 to September 2023. Other roles include Vice President and Head External R&D Innovation at Pfizer from November 2010 to August 2014, Co-founder and CEO of ModusBiomedicine from August 2009 to December 2010, and Head of Inflammation Pharmacology at Roche Pharmaceuticals from April 2001 to December 2009. Karim's academic credentials include a Research Fellowship in Immunology at Stanford University, a Postdoctoral Fellowship in Physiology at the University of California, San Francisco, a PhD in Biochemistry from UCL, and a BSc (Hons) in Biotechnology from Imperial College of Science, Technology and Medicine.